Karus Therapeutics
  • Home
  • About Karus
    • At a glance
    • Leadership
    • Investors
  • Research & Development
  • Partnering
  • Media Centre
    • Press Releases
    • Events
    • In the News
    • Publications
    • Abstracts
  • Contact Us
  • Menu Menu

Media Centre

Abstracts

Abstracts

Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors

28 April 2020/in Abstracts /by circlek

Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors.
Tsimberidou A.M., Beer P., Bendall J., Dow J., King J., McElwaine-Johnn H. and Wistuba I.I.
Abstract CT151. American Association for Cancer Research Virtual Annual Meeting I; April 27-28 2020.

/wp-content/uploads/2019/04/logo_karustx.png 0 0 circlek /wp-content/uploads/2019/04/logo_karustx.png circlek2020-04-28 15:20:312020-04-28 15:21:23Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with relapsed or refractory solid tumors

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma

10 December 2019/in Abstracts /by circlek

Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma.
Nastoupil L.J., Neelapu S.S., Davis E., Samaniego F., Fowler N.H., Westin J.R., Lee H.J., Wang M., Hagemeister F.B., Cecil A.R.L., Dow J., McHale D., Silva F., Ward P., Yavari A., Shuttleworth S.J.; and Beer P.
Abstract 4099. 61st American Society of Hematology Annual Meeting and Exposition; December 7-10 2019; Orlando, Florida (FL), USA

/wp-content/uploads/2019/04/logo_karustx.png 0 0 circlek /wp-content/uploads/2019/04/logo_karustx.png circlek2019-12-10 13:55:572020-01-13 14:35:58Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma

Targeting PI3K pathway in ibrutinib resistant diffuse large B-cell lymphoma

1 April 2017/in Abstracts, Publications /by circlek

Targeting PI3K pathway in ibrutinib resistant diffuse large B-cell lymphoma.
Jain N., Seghal L., Shuttleworth S.J., Samaniego F.
Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2366.

/wp-content/uploads/2019/04/logo_karustx.png 0 0 circlek /wp-content/uploads/2019/04/logo_karustx.png circlek2017-04-01 12:02:192019-07-11 16:06:56Targeting PI3K pathway in ibrutinib resistant diffuse large B-cell lymphoma

Pre-Clinical Evaluation of the PI3K-p110ß/δ Inhibitor KA2237 in Mantle Cell Lymphoma

3 December 2016/in Abstracts, Publications /by circlek

Pre-Clinical Evaluation of the PI3K-p110ß/δ Inhibitor KA2237 in Mantle Cell Lymphoma.
Huang S., Nastoupil L.J., Guo H., Bell T., Ahmed M., Li C.J., Wang J., Liu Y.,  Zhang V., Kim C.R., Boyle J.N., Lorence E.A., Lam L.T., Chen Z., Zhang H., Shuttleworth S.J., Nomie K., Wang M., Zhang L.
Abstract 1837. 58th ASH Annual Meeting and Exposition, San Diego, CA, December 3-6 2016.

/wp-content/uploads/2019/04/logo_karustx.png 0 0 circlek /wp-content/uploads/2019/04/logo_karustx.png circlek2016-12-03 12:03:092019-07-11 16:07:03Pre-Clinical Evaluation of the PI3K-p110ß/δ Inhibitor KA2237 in Mantle Cell Lymphoma

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity (Mainz)

10 May 2016/in Abstracts, Publications /by circlek

KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity.
Alexander R., Bone E.A., Cecil A.R.L., Colman L., Dow J., Finnemore D., Gatland A., Haque K., Lensun L., Roitt S., Rogers H., Silva F.A., Ward P., Whale A., Shuttleworth S.J.
Abstract 207. 14th CIMT Annual Meeting, Mainz, Germany, May 10-12, 2016.

/wp-content/uploads/2019/04/logo_karustx.png 0 0 circlek /wp-content/uploads/2019/04/logo_karustx.png circlek2016-05-10 12:05:312019-07-11 16:07:08KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110ß/p110δ and HDAC6 with single-agent and combination activity (Mainz)
Page 1 of 41234

Categories

  • Press Releases
  • Events
  • In the News
  • Publications
  • Abstracts
View archive
  • Privacy Policy

© Karus Therapeutics. All rights reserved

Registered in England & Wales No 05490954
VAT No 871 4126 33

LinkedIn

Created by Instinctif Partners

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OKLearn more

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only